April 11, 2022 4:51pm

Pre-open indications: 4 HITs and 3 MISS

News: Editas Medicine (EDIT -$0.85) announced the administration of EDIT-101, an experimental CRISPR gene editing medicine, to the first pediatric patient enrolled in the BRILLIANCE clinical trial, which is designed to test the safety of EDIT-101 for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder.

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.


The Dow closed DOWN -413.04 points (-1.19%); the S&P closed DOWN -75.75 points (-1.69%) while the Nasdaq closed DOWN -299.04 points (-2.18%)



The S&P and the Nasdaq fell more than -1% to -2% on Monday with losses growing deeper in the final hour of trading as rising Treasury bond yields weighed on stocks.

Data on Tuesday is expected to show U.S. consumer prices leapt to a fresh four-decade high of 8.5% in March, on a year-on-year basis, after hitting 7.9% in February, as the Ukraine conflict drives up energy costs. <Reuters>


Pre-open post: RegMed Investors’ (RMi) pre-open: Share pricing risk is weighted by week’s economics and lack of value catalysts” … https://www.regmedinvestors.com/articles/12382


RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Monday opened negative at 0 up/35 downs, stayed negative at the mid-day at 2/32 and 1 flat, ending with a negative close of 1/33 and 1 flat,
  • Friday opened negative at 4 up/29 downs, 2 flats, stayed negative at the mid-day at 10/24 and 1 flat, ending with a negative close of 8/27;


52-week or all-time lows:

  • Applied Genetic Technologies (AGTC) at $1.01
  • AVROBIO (AVRO) at $1.16
  • Adverum Biotechnologies (ADVM) at $1.19
  • Caribou Biosciences (CRBU) at $7.97
  • Homology Medicine (FIXX) at $2.34
  • Beam Therapeutics (BEAM) at $50.00


Pre-open Indications: 4 HITs: <Biostage (BSTG) closed up $0.00 with 25 shares traded, Editas Medicine (EDIT -$0.78), CRISPR Therapeutics (CRSP -$0.17), Intellia Therapeutics (NTLA -$1.33)> 3 MISS:  Beam Therapeutics (BEAM -$2.76), Caribou Biosciences (CRBU -$0.32), BioLife Solutions (BLFS -$0.38),


Key Metrics:

  • Monday - Sector volume was LOW with 1 of the 1-upside having higher than the 3-month average volume with LOW volume of 5 of 33-downside having higher than the 3-month average volume;
  • Friday - Sector volume was LOW with 2 of the 8-upside having higher than the 3-month average volume with LOW volume of 1 of 27-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was down -2.30% and the XBI was down -3.40%
  • Friday, the IBB was down -0.43% and the XBI was down -2.26%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +3.21 points or +15.17 % at 24.37
  • Friday was down -0.37 points or -1.72% at 21.18


Jumping with share pricing momentum (1 of 1):

  • uniQure NV (QURE +$0.08),

Hammered in today’s market (10 of 33):

  • Alnylam Pharmaceuticals (ALNY -$5.99 after Friday’s +$1.17),
  • Beam Therapeutics (BEAM -$2.76 after Friday’s -$1.60),
  • Ultragenyx (RARE -$2.62),
  • Fate Therapeutics (FATE -$2.15 after Friday’s -$1.59),
  • Intellia Therapeutics (NTLA -$1.33 after Friday’s -$2.96),
  • Editas Medicine (EDIT -$0.78 after Friday’s -$0.73),
  • Global Blood Therapeutics (GBT -$0.76 after Friday’s -$1.25),
  • Ionis Pharmaceuticals (IONS -$0.51 after Friday’s -$0.79),
  • Vericel (VCEL -$0.51 after Friday’s -$0.74),
  • BioLife Solutions (BLFS -$0.38 after Friday’s -$1.69),


  • Biostage (BSTG)



April, Q2/2022:

  • Monday closed negative with 1 incliner, 33 decliners and 1 flat
  • Friday closed negative with 8 incliners and 27 decliners
  • Thursday closed negative with 7 incliners, 26 decliners and 2 flats
  • Wednesday closed negative with 8 incliners, 26 decliners and 1 flat
  • Tuesday closed negative with 8 incliners, 26 decliners and 1 flat
  • Monday closed positive with 31 incliners and 4 decliners
  • Friday closed positive with 27 incliners and 6 decliners and 2 flats


The BOTTOM LINE: Worst session in more than a while as the oversold are even more undervalued.

I STILL believe, lows are looking appetizing after going as even to LOWER levels on Monday.

As I stated in last Friday night’s post, “What justifies the share pricing, it’s NOT investor advocacy?  The short-term and near-term pricing “shades” the long-term price targets.”

Volume again was also barely there … as many companies prepare for a Q1/22 response to earnings – and it might get even more ugly.

I am more than worried about investment bank pricey analyst valuations that (in my mind’s eye) have NO basis.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.